Mounjaro 7.5mg Tirzepatide Injection

Mounjaro 7.5 mg is a prescription injectable medication formulated with the active ingredient tirzepatide. Belonging to the dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist drug class, it is indicated to support glycemic control in adults with type 2 diabetes and assist in weight management and metabolic health.

As an intermediate maintenance dose, the 7.5 mg weekly injection works by activating natural incretin pathways. This dual action stimulates insulin secretion in response to elevated blood glucose, suppresses excess glucagon production, slows gastric emptying, and targets appetite pathways to enhance fullness and reduce cravings.

Key Information & Precautions

• Administration: Subcutaneous injection administered once weekly.
• Common Side Effects: Gastrointestinal symptoms such as nausea, diarrhea, decreased appetite, vomiting, constipation, and abdominal discomfort.
• Precautions: Discuss full medical history prior to use, particularly regarding risks of pancreatitis, hypoglycemia (especially when paired with secretagogues or insulin), and gastrointestinal disease. Boxed warnings apply regarding thyroid C-cell tumor risks in animal studies.